"Current treatments for osteoarthritis mostly provide symptomatic relief, and so disease-modifying drugs that target the underlying structural damage would be a game changer. But despite multiple attempts, no DMOAD is yet approved for clinical use.

Prof. Ali Mobasheri takes us through the main challenges, the work being done to address them to make these so-called utopia drugs a reality, and other advances that can offer some hope in the meantime."